Routine board refresh with no financial or strategic implications. No trading catalyst. Monitor for any future disclosures on Innoviva's investment trajectory in Syndeio BioSciences, but this filing alone does not warrant action.
INVA drugs
INVA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 19 $21.73entry
- T+1 · 6mo ago +2.35%α +1.31% · $22.24
- T+5 · 6mo ago +1.84%α −0.46% · $22.13
- T+20 · 5mo ago +4.19%α +3.20% · $22.64
- T+60 · 3mo ago −4.51%α −10.80% · $20.75
Price Chart
How similar events traded
Executive Summary
Innoviva reported the resignations of board members Derek Small and Mark DiPaolo to focus on their roles at Syndeio BioSciences, a company Innoviva has invested in and continues to support. The board elected Josephine Linden, a former Goldman Sachs partner and founder of Linden Global Strategies, as an independent director to fill the vacancies. This is a routine board transition with no disagreements disclosed, representing a neutral event for the company's operations.
Key Facts
- Derek Small and Mark DiPaolo resigned from the board on May 12, 2026, to focus on Syndeio BioSciences.
- Resignations were not due to any disagreement with Innoviva's operations, policies, or practices.
- Josephine Linden elected to the board on May 18, 2026, as an independent director, expected to serve on the Audit Committee.
- Linden is the founder of Linden Global Strategies LLC and a retired Goldman Sachs Partner and Managing Director.
- Linden receives initial RSU award of $125,000, prorated annual RSU award of $206,250, and options for 9,166 shares under the 2026 Equity Incentive Plan.
- No material transactions between Innoviva and Linden exceeding $120,000.
Financial Impact
New director compensation: $125,000 initial RSU, $206,250 prorated annual RSU, and options for 9,166 shares. Immaterial relative to $1.6B market cap.
Risk Factors
- Loss of board members with direct ties to Syndeio may reduce board-level insight into that investment.
- New director is independent and highly qualified, but the transition introduces a short period of adjustment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-228958 |
| Document: 0001193125-26-228958-index-headers.html | 0001193125-26-228958 |
| Document: 0001193125-26-228958-index.html | 0001193125-26-228958 |
| Document: 0001193125-26-228958.txt | 0001193125-26-228958 |
Track record
5 reports on INVA
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 4, 202612d ago 8-K Bearish 5/10 Entry $19.24 to $18.97 Now $18.49 +3.90% ▲ +1.40% +4.69% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $21.12 to $21.26 Now $18.49 −12.45% ▲ +0.66% +1.38% vs SPY
- May 18, 202626w ago 8-K Neutral 3/10 Viewing Entry $21.73 to $22.13 Now $18.49 −14.91% ▲ +1.84% −0.46% vs SPY
- May 6, 202627w ago 8-K Mixed 5/10 Entry $22.80 to $23.14 Now $18.49 −18.90% ▲ +1.49% −0.01% vs SPY
- Mar 27, 202633w ago 10-K/A Neutral 3/10 Entry $22.91 to $23.28 Now $18.49 −19.29% ▲ +1.61% −2.69% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers